Abstract:Pharmaceuticals are recognised among emerging contaminants, particularly in water. They have the potential to alter ecosystem dynamics, with notable examples including hormone-induced feminization of male fish and disruptions to oogenesis in invertebrates. To assess the risk posed by pharmaceuticals, it is essential to understand their amount (via Measured Environmental Concentrations MEC) and their actual effects on target species (via Predicted No Effect Concentrations PNEC). Recently, many studies have aimed to collect MEC data from around the world, but a comprehensive overview is still lacking. Thus, the objective of this study is to provide a comprehensive overview by examining recently published literature on MEC data for a wide range of pharmaceuticals. Additionally, to enable risk assessment, this study also reviewed the published literature on PNEC data and integrated it with existing databases. A total of 315 substances were selected for MEC data extraction, with the inclusion of 56 articles. The most frequently monitored locations were Cadiz Bay in Spain (90 samples), the River Thames in the UK (51), and Hrdějovice in the Czech Republic (49). Most MEC samples were collected from surface water (N=325), influent wastewater treatment plants (WWTP) (205), and effluent WWTP (118). Based on PNEC values, risk analysis identified 81 pharmaceuticals as high-risk, with the highest risk values for propranolol (risk quotient [RQ]: 29,450,000), diclofenac (395,920), and 17alpha-ethinylestradiol (95,946). Additionally, the ATC classes with the most high-risk substances were anti-infectives (J), nervous system agents (N), cardiovascular agents (C), antineoplastic agents (L), analgesics (M), and sex hormones (G). The findings of this study highlight the widespread impact of pharmaceuticals across the globe and the involvement of multiple therapeutic classes. To move beyond the current point-in-time overview, which is limited to specific locations and sampling periods, systems for continuous monitoring of pharmaceuticals should be developed. This could involve the creation of resource-efficient methods and the integration of sampling data with estimation models. Furthermore, these results could serve as a starting point for developing and implementing actions to prevent and mitigate the environmental impact of pharmaceuticals.

Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment

The environmental impact of pharmaceuticals: an evidence-mapping review of recent data on aquatic concentrations and predictable effects

Defining the data gap: what do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment?

Pharmaceutical Compounds in Aquatic Environment in China: Locally Screening and Environmental Risk Assessment

Ranking the risks of eighty pharmaceuticals in surface water of a megacity: A multilevel optimization strategy

Prioritizing pharmaceuticals based on environmental risks in the aquatic environment in China

Predicting environmental risks of pharmaceutical residues by wastewater surveillance: An analysis based on pharmaceutical sales and their excretion data

Are exposure predictions, used for the prioritization of pharmaceuticals in the environment, fit for purpose?

Environmental Occurrence and Predicted Pharmacological Risk to Freshwater Fish of over 200 Neuroactive Pharmaceuticals in Widespread Use

Prioritizing Pharmaceutical Contaminants in Great Lakes Tributaries Using Risk-Based Screening Techniques

The assessment of environmental risk related to the occurrence of pharmaceuticals in bottom sediments of the Odra River estuary (SW Baltic Sea)

Occurrence and potential risks of pharmaceutical contamination in global Estuaries: A critical review and analysis

The risk of pharmaceuticals in the aquatic environment By

Pharmaceuticals in Canadian sewage treatment plant effluents and surface waters: occurrence and environmental risk assessment

Pharmaceuticals in raw and treated water from drinking water treatment plants nationwide: Insights into their sources and exposure risk assessment

Bioaccumulation and biomagnification potential of pharmaceuticals with a focus to the aquatic environment

Ecotoxicity and environmental risk assessment of pharmaceuticals and personal care products in aquatic environments and wastewater treatment plants

Identifying targets of potential concern by a screening level ecological risk assessment of human use pharmaceuticals in China

Analyzing the potential environmental impact of NIOSH list of hazardous drugs (group 2)

Pharmaceuticals in Water: Risks to Aquatic Life and Remediation Strategies

Environmental risk assessment of psychoactive drugs in the aquatic environment